SCHEMBL20206250

SCHEMBL20206250

C/C(=C\N(C)c1ccc(NC(=O)c2cccc(Br)n2)cc1)c1cccc(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.42
ALDH1A1 P00352 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.42
MCL1 Q07820 2/20 0.42
LMNA P02545 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KAT6A Q92794 1/20 0.41
NAMPT P43490 1/20 0.41
ACKR3 P25106 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206125 0.85 NAMPT (0.52) GAANPC1RAB9AHDAC3HDAC1
SCHEMBL20206126 0.82 KAT6A (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL20206127 0.81 NAMPT (0.57) GAAALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL24021427 0.81 GRM5 (0.49) GAAHDAC3HDAC1HDAC2HDAC8
SCHEMBL20206151 0.81 GAA (0.51) GAAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL20206152 0.79 NAMPT (0.59) GAAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL23898933 0.73 GAA (0.61) GAAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL20189983 0.73 STAT3 (0.52) GAAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7074306 0.70 NAMPT (0.57) ALDH1A1NPC1RAB9AHDAC3HDAC1
SCHEMBL20206124 0.70 P2RY14 (0.49) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018098367-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-05-31 WO disclosed